Everything tagged "growth" across the TickerSpark archives.
TTM Technologies is benefiting from a sharp mix shift toward AI infrastructure and aerospace and defense, with Q2 revenue up 37% and EPS up 71%. The stock still carries valuation and execution risk, but the report argues the growth runway supports a Buy.
RTX is benefiting from a $340.0B backlog, double-digit Q3 sales growth, and stronger defense and commercial aerospace demand. The stock looks solid operationally, but premium valuation keeps it at a Hold.
FICO posted 26% revenue growth and 41% EPS growth as Scores and platform ARR accelerated, but leverage remains the key risk. The stock earns a Buy on strong operating momentum, though valuation and debt keep the setup moderate-risk.
Rollins remains a high-quality recurring-revenue pest control business, but recent margin pressure and inconsistent earnings beats support a cautious Hold. Revenue is still growing, yet the stock’s valuation leaves less room for disappointment.
Tenet Healthcare delivered a strong Q2 with rising hospital margins, accelerating ambulatory EBITDA, and higher 2026 guidance. The stock still screens as a Buy despite debt and payer-mix risk.
Wabtec is executing well with strong backlog, margin expansion, and recurring aftermarket revenue. The stock looks like a quality compounder, but the current price already reflects much of the upside, keeping the call at Hold.
Tower Semiconductor posted record Q2 revenue and is benefiting from surging silicon photonics demand tied to AI data-center connectivity. The stock looks attractive on growth, but valuation already reflects much of the improvement.
VeriSign’s core .com and .net franchise continues to deliver strong growth, record registrations, and elite margins. But the stock already reflects much of that quality, leaving the shares at a Hold despite solid operating momentum.
Comfort Systems USA is riding powerful data-center and industrial demand, with revenue up 50.3% and a record $14.1B backlog. The stock earns a Buy, but valuation is already pricing in much of the boom.
DexCom posted 13% Q2 revenue growth, 46% EPS growth, and raised 2026 guidance, but the stock still screens as a Hold at a rich valuation. The report highlights expanding reimbursement, strong G7 15 Day adoption, and a growing opportunity in non-insulin type 2 diabetes.
Kinder Morgan is benefiting from stronger natural gas demand, a $9.6B backlog, and rising Q2 EBITDA, but leverage and valuation keep it from looking cheap.
Packaging Corp of America has a constructive medium-term setup as demand, pricing, and Greif integration support earnings recovery. But higher debt and a 31.1 trailing P/E leave less room for disappointment.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime